BRPI0920608A2 - compostos quimicos - Google Patents

compostos quimicos

Info

Publication number: BRPI0920608A2
Authority: BR; Brazil
Prior art keywords: chemical compounds; compounds; chemical
Prior art date: 2008-09-29

Application number

BRPI0920608A

Other languages

English (en)

Inventor

Mantoulidis Andreas

Ettmayer Peter

Steurer Steffen

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-29

Filing date

2009-09-28

Publication date

2019-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920608(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-28 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2019-09-24 Publication of BRPI0920608A2 publication Critical patent/BRPI0920608A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0920608A 2008-09-29 2009-09-28 compostos quimicos BRPI0920608A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08165437		2008-09-29
PCT/EP2009/062551 WO2010034838A2 (en)	2008-09-29	2009-09-28	New chemical compounds

Publications (1)

Publication Number	Publication Date
BRPI0920608A2 true BRPI0920608A2 (pt)	2019-09-24

Family

ID=40019293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920608A BRPI0920608A2 (pt)	2008-09-29	2009-09-28	compostos quimicos

Country Status (20)

Country	Link
US (1)	US8778929B2 (pt)
EP (1)	EP2350052B1 (pt)
JP (1)	JP5603869B2 (pt)
KR (1)	KR20110063574A (pt)
CN (1)	CN102227421A (pt)
AR (1)	AR073700A1 (pt)
AU (1)	AU2009295855A1 (pt)
BR (1)	BRPI0920608A2 (pt)
CA (1)	CA2738448A1 (pt)
CL (1)	CL2011000691A1 (pt)
CO (1)	CO6351739A2 (pt)
EA (1)	EA201100564A1 (pt)
EC (1)	ECSP11010930A (pt)
IL (1)	IL211744A0 (pt)
MA (1)	MA32656B1 (pt)
MX (1)	MX2011003292A (pt)
PE (1)	PE20110294A1 (pt)
TW (1)	TW201018670A (pt)
UY (1)	UY32146A (pt)
WO (1)	WO2010034838A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20090837A1 (es)	2007-07-02	2009-07-24	Boehringer Ingelheim Int	Nuevos compuestos quimicos
AR073501A1 (es)	2008-09-08	2010-11-10	Boehringer Ingelheim Int	Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
BRPI0920608A2 (pt)	2008-09-29	2019-09-24	Boehringer Ingelheim Int	compostos quimicos
JP5603883B2 (ja)	2009-02-17	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
JP2011057661A (ja) *	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
JP5871896B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−ｒａｆキナーゼインヒビター
JP5871897B2 (ja) *	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジルトリアゾール
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en)	2011-02-02	2014-11-18	Boehringer Ingelheim International Gmbh	Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP6165733B2 (ja) *	2011-09-16	2017-07-19	ノバルティスアーゲー	Ｎ−置換ヘテロシクリルカルボキサミド類
RU2622015C2 (ru)	2011-11-11	2017-06-08	Новартис Аг	Способ лечения пролиферативного заболевания
ES3037966T3 (en)	2011-11-23	2025-10-08	Array Biopharma Inc	Pharmaceutical formulations
CA2769821C (en)	2012-02-28	2020-08-11	Michael Hatzinikolas	Self-releasing structural assembly
US9315489B2 (en)	2012-05-15	2016-04-19	Novartis Ag	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
MX2014013373A (es)	2012-05-15	2015-08-14	Novartis Ag	Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
AP3613A (en)	2012-05-15	2016-02-29	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
BR112014027244A2 (pt)	2012-05-15	2017-06-27	Novartis Ag	derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1
EP3319968A1 (en)	2015-07-06	2018-05-16	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007756A1 (en)	2015-07-06	2017-01-12	Rodin Therapeutics, Inc	Hetero-halo inhibitors of histone deacetylase
JP6545275B2 (ja) *	2015-10-23	2019-07-17	田辺三菱製薬株式会社	新規含窒素芳香族複素環化合物
CN106316864A (zh) *	2016-08-22	2017-01-11	苏州天马精细化学品股份有限公司	4‑甲基‑3‑三氟甲基苯胺的制备方法
WO2018132531A1 (en)	2017-01-11	2018-07-19	Rodin Therapeutics, Inc.	Bicyclic inhibitors of histone deacetylase
CA3071861A1 (en)	2017-08-07	2019-02-14	Rodin Therapeutics, Inc.	Bicyclic inhibitors of histone deacetylase
CN108707147A (zh) *	2018-06-20	2018-10-26	桑文军	一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
JP2021534152A (ja) *	2018-08-14	2021-12-09	バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc.	Ａｓｋ１阻害剤
EP3886854A4 (en)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
CN116761801A (zh) *	2021-03-12	2023-09-15	四川科伦博泰生物医药股份有限公司	具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CN115772121A (zh) *	2021-09-06	2023-03-10	南通诺泰生物医药技术有限公司	2-甲胺基-3-羟甲基吡啶的制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU507066B1 (en)	1977-09-06	1980-01-31	Sumitomo Chemical Company, Limited	2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja)	1989-09-20	1991-07-29	Fuji Photo Film Co Ltd	カラー画像形成方法
AU699727B2 (en)	1995-02-02	1998-12-10	Smithkline Beecham Plc	Indole derivatives as 5-HT receptor antagonist
WO1997003967A1 (en)	1995-07-22	1997-02-06	Rhone-Poulenc Rorer Limited	Substituted aromatic compounds and their pharmaceutical use
AU3998400A (en)	1999-02-09	2000-08-29	3-Dimensional Pharmaceuticals, Inc.	Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en)	2000-02-24	2003-03-11	Cheryl P. Kordik	Amino pyrazole derivatives useful for the treatment of obesity and other disorders
WO2002062792A1 (en)	2001-02-02	2002-08-15	Takeda Chemical Industries, Ltd.	Jnk inhibitor
ATE455104T1 (de)	2001-11-01	2010-01-15	Icagen Inc	Pyrazolamide zur anwendung in der behandlung von schmerz
US20040010027A1 (en)	2001-12-17	2004-01-15	Pharmacia & Upjohn Spa	Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja)	2002-01-09	2005-06-23	Ajinomoto Co Inc	アシルスルホンアミド誘導体
ES2265596T3 (es)	2002-11-27	2007-02-16	Boehringer Ingelheim Pharmaceuticals Inc.	Derivados de 1,2,3-triazol-amida como inhibidores de citocinas.
MXPA06002853A (es)	2003-09-11	2006-06-14	Kemia Inc	Inhibidores citoquina.
CA2539117A1 (en)	2003-09-24	2005-04-07	Methylgene Inc.	Inhibitors of histone deacetylase
WO2005040152A1 (en)	2003-10-20	2005-05-06	E.I. Dupont De Nemours And Company	Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
CA2547410C (en)	2003-12-03	2013-07-30	Boehringer Ingelheim Pharmaceuticals, Inc.	1,2,3-triazole amide derivatives as inhibitors of cytokie production
PT1725544E (pt)	2004-03-09	2009-07-02	Boehringer Ingelheim Pharma	3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
US7485657B2 (en)	2004-05-12	2009-02-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
US7531560B2 (en)	2004-11-10	2009-05-12	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
US7696202B2 (en)	2004-11-10	2010-04-13	Synta Pharmaceuticals Corp.	IL-12 modulatory compounds
JP2007076376A (ja)	2005-09-09	2007-03-29	Yanmar Co Ltd	トラクタ
WO2007056016A2 (en)	2005-11-02	2007-05-18	Kemia, Inc.	Bisamide cytokine inhibitors
WO2007075896A2 (en)	2005-12-22	2007-07-05	Kemia, Inc.	Heterocyclic cytokine inhibitors
US20070155746A1 (en) *	2005-12-23	2007-07-05	Kalypsys, Inc.	Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2009536618A (ja)	2006-04-18	2009-10-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４−及び５−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
PE20120006A1 (es)	2006-05-15	2012-02-02	Boehringer Ingelheim Int	Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
CA2654898A1 (en)	2006-07-07	2008-10-01	Boehringer Ingelheim International Gmbh	New chemical compounds
US20080045489A1 (en)	2006-07-07	2008-02-21	Jianhua Chao	3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
WO2008008234A1 (en)	2006-07-07	2008-01-17	Targegen, Inc.	2-amino-5-substituted pyrimidine inhibitors
AU2007269163B2 (en)	2006-07-07	2011-07-28	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
PE20080906A1 (es) *	2006-08-17	2008-07-05	Kemia Inc	Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (en)	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008089034A2 (en)	2007-01-11	2008-07-24	Kemia, Inc.	Cytokine inhibitors
AU2008221263B2 (en)	2007-03-01	2012-02-23	Novartis Ag	Pim kinase inhibitors and methods of their use
PE20090837A1 (es)	2007-07-02	2009-07-24	Boehringer Ingelheim Int	Nuevos compuestos quimicos
US20100240657A1 (en)	2007-07-02	2010-09-23	Boehringer Ingelheim International Gmbh	Chemical compounds
SG183036A1 (en)	2007-07-17	2012-08-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
EA019722B1 (ru)	2008-07-24	2014-05-30	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
AR073501A1 (es)	2008-09-08	2010-11-10	Boehringer Ingelheim Int	Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
BRPI0920608A2 (pt)	2008-09-29	2019-09-24	Boehringer Ingelheim Int	compostos quimicos
JP5603883B2 (ja)	2009-02-17	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
JP5871897B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジルトリアゾール
JP5871896B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−ｒａｆキナーゼインヒビター
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en)	2011-01-27	2013-01-24	Boehringer Ingelheim International Gmbh	Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en)	2011-02-02	2014-11-18	Boehringer Ingelheim International Gmbh	Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

2009
- 2009-09-28 BR BRPI0920608A patent/BRPI0920608A2/pt not_active IP Right Cessation
- 2009-09-28 MX MX2011003292A patent/MX2011003292A/es not_active Application Discontinuation
- 2009-09-28 US US13/121,241 patent/US8778929B2/en active Active
- 2009-09-28 EP EP09783505.2A patent/EP2350052B1/en active Active
- 2009-09-28 UY UY0001032146A patent/UY32146A/es not_active Application Discontinuation
- 2009-09-28 JP JP2011528358A patent/JP5603869B2/ja active Active
- 2009-09-28 CA CA2738448A patent/CA2738448A1/en not_active Abandoned
- 2009-09-28 TW TW098132738A patent/TW201018670A/zh unknown
- 2009-09-28 PE PE2011000796A patent/PE20110294A1/es not_active Application Discontinuation
- 2009-09-28 EA EA201100564A patent/EA201100564A1/ru unknown
- 2009-09-28 KR KR1020117009679A patent/KR20110063574A/ko not_active Withdrawn
- 2009-09-28 CN CN2009801476559A patent/CN102227421A/zh active Pending
- 2009-09-28 AU AU2009295855A patent/AU2009295855A1/en not_active Abandoned
- 2009-09-28 WO PCT/EP2009/062551 patent/WO2010034838A2/en not_active Ceased
- 2009-09-28 AR ARP090103730A patent/AR073700A1/es unknown
2011
- 2011-03-15 IL IL211744A patent/IL211744A0/en unknown
- 2011-03-25 CO CO11036947A patent/CO6351739A2/es not_active Application Discontinuation
- 2011-03-28 MA MA33729A patent/MA32656B1/fr unknown
- 2011-03-29 EC EC2011010930A patent/ECSP11010930A/es unknown
- 2011-03-29 CL CL2011000691A patent/CL2011000691A1/es unknown

Also Published As

Publication number	Publication date
AU2009295855A1 (en)	2010-04-01
KR20110063574A (ko)	2011-06-10
ECSP11010930A (es)	2011-04-29
CL2011000691A1 (es)	2011-07-29
EP2350052B1 (en)	2014-08-13
TW201018670A (en)	2010-05-16
UY32146A (es)	2010-04-30
US8778929B2 (en)	2014-07-15
EP2350052A2 (en)	2011-08-03
IL211744A0 (en)	2011-06-30
WO2010034838A3 (en)	2010-11-18
PE20110294A1 (es)	2011-05-26
WO2010034838A2 (en)	2010-04-01
EA201100564A1 (ru)	2011-12-30
JP5603869B2 (ja)	2014-10-08
US20110312939A1 (en)	2011-12-22
CA2738448A1 (en)	2010-04-01
AR073700A1 (es)	2010-11-24
CN102227421A (zh)	2011-10-26
CO6351739A2 (es)	2011-12-20
MX2011003292A (es)	2011-04-21
MA32656B1 (fr)	2011-09-01
JP2012504114A (ja)	2012-02-16

Publication	Publication Date	Title
BRPI0920608A2 (pt)	2019-09-24	compostos quimicos
BRPI0821627A2 (pt)	2014-10-14	Compostos químicos
BRPI0814601A2 (pt)	2019-09-24	compostos químicos
DOP2012000045A (es)	2012-05-31	Compuestos químicos
DK2288375T3 (da)	2012-05-21	Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt)	2015-12-29	compostos
DK2242759T3 (da)	2012-12-17	Forbindelser
BRPI0922351A2 (pt)	2018-06-05	compostos orgânicos
BRPI0922700A2 (pt)	2015-08-11	Compostos orgânicos
BRPI0922808A2 (pt)	2018-05-29	compostos orgânicos
BRPI0922348A2 (pt)	2015-08-11	Compostos orgânicos
BRPI0922131A2 (pt)	2015-08-18	Compostos orgânicos
BRPI0922809A2 (pt)	2018-05-29	compostos orgânicos
BRPI0913966A2 (pt)	2015-11-17	compostos orgânicos
BRPI0914698A2 (pt)	2015-10-20	compostos orgânicos
BRPI0909417A2 (pt)	2015-12-08	compostos orgânicos
BRPI0915018A2 (pt)	2015-10-27	compostos orgânicos
DK2310359T3 (da)	2014-04-07	Organiske forbindelser
BRPI0813500A2 (pt)	2015-01-06	Compostos antivirais
BRPI0821086A2 (pt)	2014-10-07	Compostos inseticidas
BRPI0714512A2 (pt)	2015-06-16	Compostos químicos
BRPI0917574A2 (pt)	2015-11-17	compostos orgânicos
BRPI0921826A2 (pt)	2016-01-12	compostos orgânicos
BRPI0907611A2 (pt)	2015-07-21	Compostos orgânicos
DK2323972T3 (da)	2013-10-07	C7-fluor-substituerede tetracylinforbindelser

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.